HER2-Negative Breast Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "HER2-Negative Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report
• DelveInsight's HER2-Negative Breast Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for HER2-Negative Breast Cancer treatment.
• The leading companies working in the HER2-Negative Breast Cancer Market include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others.
• Promising HER2-Negative Breast Cancer Pipeline Therapies in the various stages of development include MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Anastrozole, OP-1250, and others.
• November 2023: Oana Danciu announced a study of Phase 2 clinical trials for Ribociclib, Fulvestrant, Anastrozole, Letrozole, and Exemestane. This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer. A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer.
• October 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD9833 and Anastrozole. The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.
• October 2023: SynDevRx Inc. announced a study of Phase 1 & 2 clinical trials for Evexomostat. The purpose of this study is to characterize the safety of the triplet drug combination (alpelisib, fulvestrant plus evexomostat), to test whether evexomostat, when given in combination with alpelisib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number of anti-diabetic medications needed to control the hyperglycemia for patients deemed at risk for alpelisib-induced hyperglycemia (baseline elevated HbA1c or well-controlled type 2 diabetes), and to assess preliminary anti-tumor efficacy and changes in key biomarkers and quality of life in this patient population.

Request a sample and discover the recent advances in HER2-Negative Breast Cancer Treatment Drugs @ HER2-Negative Breast Cancer Pipeline Report- https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the HER2-Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

HER2-Negative Breast Cancer Overview
HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors.

Find out more about HER2-Negative Breast Cancer Therapeutics Assessment @ HER2-Negative Breast Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-Negative Breast Cancer Emerging Drugs Profile

Giredestrant : Genentech
Giredestrant is a novel investigative small molecule that works as selective estrogen receptor degrader (SERD) by targeting the estrogen receptor (ER). The drug candidate is a new molecular entity (NME) which is administered through oral route. Preclinical studies suggest that Giredestrant is orally bioavailable and competitively inhibits the binding of estrogen to the ER. In preclinical models, Giredestrant has been shown to restrain the normally dynamic behavior of both wild-type and mutant ER, immobilizing the ER and attenuating the expression of its target genes. Currently, the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

Inavolisib : Genentech
Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα. In preclinical models, the molecule showed potent selective inhibition of PI3Kα and has increased potency to mutant PI3K cells over wild type. It is less sensitive for the other three PI3K isoforms. Inavolisib binds to the ATP-binding site of PI3Kα, thereby blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling as shown in preclinical models. Moreover, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduction of pathway activity. Currently the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

CX-2009 : CytomX Therapeutics
CX-2009 (Praluzatamab ravtansine) is a conditionally activated antibody-drug conjugate (ADC) comprised of a CD166-directed humanized monoclonal antibody conjugated to the maytansinoid DM4, a tubulin inhibitor. Praluzatamab ravtansine utilizes CytomX Probody® platform technology, which incorporates a masking peptide to cover and block the cellular binding region of the antibody. Tethered to the antibody via a protease-cleavable linker, currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

H3B 6545 : H3 Biomedicine
H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer. H3B- 6545, a first-in-class small molecule selective estrogen receptor covalent antagonist (SERCA) demonstrates activity in tumor models that harbor wild-type or mutant ERα.4 H3B-6545 activity against ERα mutants resistant to standard therapy provides an opportunity to target a currently unmet medical need both as a single agent and in combination with other breast cancer therapies. Currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

RGT-419B : Regor Therapeutics
RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. Results from non-clinical studies showed that RGT-419B demonstrated full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 inhibitors. Additionally, RGT-419B's tumor cell suppression was further augmented when combined with a selective estrogen receptor down-regulator or a PI3K signaling pathway inhibitor. Currently, the drug is in Phase I stage of its development for the treatment of HER2 negative breast cancer.

HER2-Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the HER2-Negative Breast Cancer therapies. The HER2-Negative Breast Cancer companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.

DelveInsight's HER2-Negative Breast Cancer pipeline report covers around 85+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical


HER2-Negative Breast Cancer Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging HER2-Negative Breast Cancer Pipeline Therapies @ HER2-Negative Breast Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HER2-Negative Breast Cancer Pipeline Report
• Coverage- Global
• HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HER2-Negative Breast Cancer Companies- AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others.
• HER2-Negative Breast Cancer Pipeline Therapies- MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Anastrozole, OP-1250, and others.

Dive deep into rich insights for new drugs for HER2-Negative Breast Cancer Treatment, Visit @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. HER2-Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-Negative Breast Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. HER2-Negative Breast Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Capivasertib + Fulvestrant: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. Inavolisib: Roche
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Afuresertib + Fulvestrant: Laekna
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. HER2-Negative Breast Cancer Key Companies
23. HER2-Negative Breast Cancer Key Products
24. HER2-Negative Breast Cancer- Unmet Needs
25. HER2-Negative Breast Cancer- Market Drivers and Barriers
26. HER2-Negative Breast Cancer- Future Perspectives and Conclusion
27. HER2-Negative Breast Cancer Analyst Views
28. HER2-Negative Breast Cancer Key Companies
29. Appendix

For further information on the HER2-Negative Breast Cancer Pipeline therapeutics, reach out to HER2-Negative Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

This release was published on openPR.